April 22, 2024

bioRN M2M with Cytion | Your Cell Culture Questions Answered

bioRN M2M with Cytion | Your Cell Culture Questions Answered

Join Cytion and bioRN for expert insights at the upcoming bioRN Member to Member session: Your Questions on Cell Lines, Cell Culture and Cell Banking answered. Get practical answers to real-world challenges.

On 15 July, we are visiting Cytion:  for a practical discussion on the challenges researchers encounter every day when working with cell cultures. Rather than a traditional company presentation, this session focuses on practical experience, troubleshooting and lessons learned from everyday laboratory work.

Submit your question during registration and selected questions will be discussed live during the event. Plus: Get an exclusive behind-the-scenes look at Cytion’s facilities and learn what happens before a cell line ever reaches your lab.

Cytion is a global leader in authenticated cell lines, serving as a trusted repository of high-quality, contamination-free biological resources. Founded in 2004 as Cell Lines Service, the company has curated over 1,000 cell lines from diverse tumors, tissues, and species. Its mission is to safeguard scientific assets and provide researchers with reliable research reagents. With services including Cell Banking, Cell Culture Scale-Up, Assay-Ready Cell Manufacture, STR analysis, and mycoplasma testing, Cytion ensures authenticity and reproducibility – empowering innovation and advancing research, cell by cell.

Grab your coffee or lunch and dial in: 

When: July 15 at 12pm, digital (Zoom) – Register via the Link and submit your questions in advance. You will receive the Zoom link after your registration.

Looking forward to seeing you there!

 

 

register now

Our latest News

discover more
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, 2026 — VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven computational partner for modern […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp